Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sight SciencesSGHT +4.36%73 14-Day RSI is 44.57 as of Jul. 26, 2026. GuruFocus rates SGHT with a GF Score™ of 73/100 and a GF Value™ of $4.52 (Fairly Valued). The stock has 3 warning signs investors should review. Among 867 Medical Devices & Instruments companies, Sight Sciences ranks worse than 50.06% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-26), Sight Sciences's 14-Day RSI is 44.57.
The industry rank for Sight Sciences's 14-Day RSI or its related term are showing as below:
SGHT's 14-Day RSI is ranked worse than 50.06% of 867
companies
in the Medical Devices & Instruments industry
Industry Median: 44.57
vs SGHT: 44.57
Sight Sciences (NAS:SGHT) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Sight Sciences 14-Day RSI Related Terms
SGHT vs SENS, LAB, TMCI: 14-Day RSI Comparison
For the Medical Devices subindustry, Sight Sciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Sight Sciences's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (SGHT) has a 14-Day RSI of 44.57 as of Jul. 26, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Sight Sciences and its competitors. According to the industry distribution chart, Sight Sciences ranks #434 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 50.1%.
Is Sight Sciences' 14-Day RSI too high?
Sight Sciences' current 14-Day RSI is 44.57. The Medical Devices & Instruments industry median 14-Day RSI is 44.57. Sight Sciences' value of 44.57 is 0% at this industry median. Based on the distribution chart, Sight Sciences ranks #434 out of 867 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sight Sciences has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' 14-Day RSI compare to SENS and LAB?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #434 out of 867 companies for 14-Day RSI. This places Sight Sciences in the lower half of its industry. The industry median 14-Day RSI is 44.57. Sight Sciences' value of 44.57 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 44.57, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sight Sciences's current 14-Day RSI of 44.57 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 44.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current 14-Day RSI is 44.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Fairly Valued. The stock's GF Value™ is $4.52, compared to a current price of $4.91 — trading 8.6% above its estimated fair value. The current 14-Day RSI is 44.57 and 0% at the Medical Devices & Instruments industry median of 44.57. Sight Sciences' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Sight Sciences (SGHT), the current 14-Day RSI is 44.57 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $4.91 is trading 8.6% above its estimated GF Value™ of $4.52.
GuruFocus considers Sight Sciences to be Fairly Valued.
Key valuation signals for SGHT:
14-Day RSI: 44.57
GF Value™: $4.52 vs. price of $4.91 (8.6% above fair value)
Industry Position: 0% at the Medical Devices & Instruments median (#434 of 867)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
73GF Score
Get the complete analysis for SGHT
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
